自拟参川生骨胶囊联合降钙素治疗骨质疏松性胸腰椎骨折疗效观察

Effect observation of Shenchuanshenggu capsule combined with calcitonin in osteoporotic thoracolumbar fracture

目的观察自拟参川生骨胶囊联合降钙素治疗骨质疏松性胸腰椎骨折的疗效。方法将骨质疏松伴胸腰椎骨折患者120例随机分为治疗组、对照A组和对照B组,各组40例。3组均及时采用骨折常规治疗,在此基础上治疗组加用降钙素鼻喷剂喷鼻,同时口服参川生骨胶囊;对照A组加用降钙素鼻喷剂喷鼻;对照B组加服参川生骨胶囊。观察每组临床疗效和用药前后骨转换指标变化及骨密度(BMD)。结果治疗组总有效率为97.5%优于对照A组的82.5%和对照B组的87.5%(P<0.05)。治疗6个月后,治疗组碱性磷酸酶(ALP)、骨钙素(BGP)水平低于对照A、B组(P<0.05)。结论自拟参川生骨胶囊联合降钙素治疗骨质疏松性胸腰椎骨折在缓解疼痛及促进骨折愈合方面疗效优于单独参川生骨胶囊或降钙素治疗,且无明显不良反应,值得推广应用。

Objective To observe the effect of Shenehuanshenggu capsule combined with calcitonin in osteoporotic thoracolumbar fracture. Methods 120 cases patients with osteoporotic thoracolumbar fracture were randomly divided into treatment group, A control group and B control group, each of 40 cases. Treatment group were given conventional treatment of fracture and Shenchuanshenggu capsule combined with calcitonin, A control group were given conventional treatment of fractures and calcitonin nasal spray, B control group were given conventional treatment of fracture and Shenehuanshenggu capsule. Observed the clinical efficacy and bone turnover marker, BMD before and after treatment of three groups. Results The total effective rate of treatment group（97.5% ） was better than that of A control group（82.5% ） and B control group（87.5% ） （P 〈 0.05 ）. 6 months after treatment, alkaline phosphatase（ ALP）, osteocalcin（BGP） level of treatment group were lower than those of A, B control group （ P 〈 0. 05 ）. Conclusion The efficacy of Shenehuanshenggu capsule combined with caleitonin in osteoporotic thoracolumbar fracture on relieving pain and promoting fracture healing is better than Shenchuanshenggu capsule or calcitonin alone, which has no significant adverse reaction.